文献速递泌尿男性生殖肿瘤支持与姑息治疗

STAMINA整合生活方式干预减轻前列腺癌雄激素剥夺治疗相关不良反应:多中心随机试验

An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.
PubMed 文献 · Lancet Oncol · 2026-09-04

STAMINA是一项在英国15个NHS信托开展的多中心随机试验,纳入700例接受ADT的前列腺癌男性,按5:4随机分配至STAMINA生活方式干预(12个月监督下有氧和抗阻运动、饮食建议、行为支持及健身房会员)或优化常规照护。干预相关严重不良事件3例,均恢复,无治疗相关死亡。

要点

  • STAMINA干预可改善ADT前列腺癌患者12个月时的前列腺癌特异性生活质量和疲劳。
  • 干预相关严重不良事件3例(短暂意识丧失、腿痛或无力、背痛),均恢复,无治疗相关死亡。

核心结论

  • STAMINA生活方式干预优于优化常规照护,可改善ADT前列腺癌患者12个月时的癌症特异性生活质量和疲劳。
  • 该干预符合最佳实践指南,可在英格兰NHS信托实施,为临床医生提供监督下运动及饮食建议干预的明确依据。

研究设计与样本

  • 多中心随机试验,在英国15个NHS信托开展,纳入接受ADT的前列腺癌男性。
  • 共700例随机分配(5:4)至STAMINA生活方式干预(n=389)或优化常规照护(n=311),按年龄、ADT时长、化疗或雄激素受体通路抑制剂治疗及放疗分层。
  • STAMINA干预包括12个月监督下有氧和抗阻运动、饮食建议、行为支持及免费健身房会员;优化常规照护包括临床医生培训、教育材料、行为提示及运动安全检查。
  • 主要终点为12个月时FACT-P和FACIT-F评分,按意向治疗分析。

主要发现

  • STAMINA组发生3例干预相关严重不良事件(短暂意识丧失、腿痛或无力、背痛),所有参与者均恢复,无治疗相关死亡。
  • 主要终点数据:STAMINA组345/389例(89%)可评估,优化常规照护组251/311例(81%)可评估。

临床怎么用

  • 临床医生可基于STAMINA方案为接受ADT的前列腺癌患者识别并处方监督下运动及饮食建议干预,以减轻ADT相关不良反应。
  • 该干预可在英格兰NHS信托实施,符合最佳实践指南。

局限性

  • 参与者知晓治疗分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer causes substantial adverse effects. Despite consistent national and international guideline recommendations, supervised exercise is rarely integrated into care. We aimed to determine whether the STAMINA lifestyle intervention, embedded into cancer care, would improve cancer-specific quality of life and fatigue versus behaviourally Optimised Usual Care in men with prostate cancer in England. METHODS: STAMINA was a multicentre, randomised trial done across 15 UK National Health Service (NHS) trusts in England. Men on ADT for prostate cancer were eligible. Participants were randomly assigned (5:4) via computer-generated minimisation, stratified by age, ADT duration, chemotherapy or androgen receptor pathway inhibitor therapy, and radiotherapy, to the STAMINA lifestyle intervention or to Optimised Usual Care. Participants were aware of treatment allocation. The STAMINA lifestyle intervention comprised supervised aerobic and resistance exercise for 12 months, dietary advice, behavioural support, and complimentary gym membership. Optimised Usual Care comprised clinician training, educational materials, behavioural prompts, and safety-to-exercise checks. Primary outcomes were the Functional Assessment of Cancer Therapy-prostate (FACT-P) and the Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) subscale at 12 months, analysed by intention to treat (according to randomised treatment). This trial is registered with ISRCTN (ISRCTN46385239), and recruitment is complete. FINDINGS: Between Jan 20, 2022, and June 12, 2023, 700 men were randomly assigned to STAMINA lifestyle intervention (n=389) or Optimised Usual Care (n=311). Median age was 71·6 years (IQR 66·3-76·0), and 680 (97%) of 700 participants were White. Primary outcome data were available for 345 (89%) of 389 participants in the STAMINA lifestyle intervention group and 251 (81%) of 311 in the Optimised Usual Care group. The STAMINA lifestyle intervention was superior to Optimised Usual Care in terms of FACT-P score (adjusted mean difference 4·5, 97·232% CI 1·7-7·2; p=0·0004) and FACIT-F score (1·9, 0·4-3·4; p=0·0068). Three intervention-related serious adverse events occurred in the STAMINA lifestyle intervention group (transient loss of consciousness, leg pain or weakness, and back pain); all participants recovered. No treatment-related deaths occurred. INTERPRETATION: The STAMINA lifestyle intervention meets best practice guidelines, can be implemented in NHS trusts in England, and offers clinicians a clear basis for identification and prescription of a supervised exercise and dietary advice intervention to mitigate negative effects associated with ADT. FUNDING: National Institute for Health Research.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Bourke L, Rosario DJ, Reale S, et al. An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial. Lancet Oncol. 2026. PMID: 42697217. doi:10.1016/S1470-2045(26)00304-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。